Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FID-007 in Head and Neck Cancer
NCT06338657Phase 1Terminated
- Sponsor
- University of Southern California
- Start
- Apr 2024
- Primary completion
- Sep 2025
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fid-007 in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Southern California. Primary endpoint: Phenotypical and functional changes of different T cell subsets within the tumor microenvironment. Started Apr 2024; status: terminated.
02
Drugs
fid-007
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06338657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06338657.